Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

62.78
+0.38000.61%
Post-market: 64.011.23+1.96%19:49 EDT
Volume:1.36M
Turnover:85.55M
Market Cap:6.17B
PE:26.85
High:64.00
Open:62.45
Low:60.53
Close:62.40
Loading ...

Sarepta Selloff Seen as Buying Opportunity -- Market Talk

Dow Jones
·
19 Mar

Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)

TIPRANKS
·
19 Mar

BUZZ-Street View: Benefits of Sarepta's gene therapy still outweighs the risk despite patient death

Reuters
·
19 Mar

Sarepta weakness ‘compelling’ buying opportunity, says Mizuho

TIPRANKS
·
19 Mar

Sarepta Therapeutics’ Elevidys: Maintaining a Buy Rating Amid Safety Concerns and Low Adverse Effect Incidence

TIPRANKS
·
19 Mar

Sarepta Therapeutics Is Maintained at Hold by Deutsche Bank

Dow Jones
·
19 Mar

Post-Bell | Wall Street Ends Lower; Tesla Sinks 5%; Nvidia Falls 3%; Meta and Palantir Drop 4%; Tiger Brokers Soars 22%

Tiger Newspress
·
19 Mar

Sarepta Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
19 Mar

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today

StockStory
·
18 Mar

Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley

TIPRANKS
·
18 Mar

Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink

TIPRANKS
·
18 Mar

Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys

TIPRANKS
·
18 Mar

Sarepta shares to dislocate from fundamentals after patient death, says JPMorgan

TIPRANKS
·
18 Mar

Sarepta Selloff Seen as Overdone -- Market Talk

Dow Jones
·
18 Mar

Sarepta Therapeutics Shares Down 24.3%; Co Reports Patient Death Following Treatment With Its Gene Therapy

THOMSON REUTERS
·
18 Mar

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Benzinga
·
18 Mar

Sarepta Therapeutics Price Target Maintained With a $163.00/Share by Cantor Fitzgerald

Dow Jones
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics

Reuters
·
18 Mar

Sarepta Therapeutics stock falls after DMM patient dies of liver failure

Dow Jones
·
18 Mar

Sarepta Therapeutics Says Patient Who Passed Away After Treatment With Elevidys Was 16 Years Old, Received Treatment in December - Statement

THOMSON REUTERS
·
18 Mar